Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Pancreatic Neoplasms × anlotinib × Clear all

Phase

Status

Recruiting 2 Unknown 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Thyroid Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1 Pancreatic Neoplasms 1 NSCLC 1 Lung Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Medullary 1 Brain Neoplasms 1 Advanced Solid Tumors 1 Advanced Malignancy 1 Advanced Cancer 1 Adenocarcinoma of Lung 1

Interventions

Gemcitabine 328 Fluorouracil 84 Oxaliplatin 70 Capecitabine 66 Albumin-Bound Paclitaxel 64 Radiotherapy 62 130-nm albumin-bound paclitaxel 61 Leucovorin 52 Erlotinib Hydrochloride 46 Irinotecan 45 Cisplatin 43 Bevacizumab 30 Radiosurgery 29 pembrolizumab 25 Docetaxel 25 Taxes 23 Nivolumab 23 Cetuximab 20 Pancreaticoduodenectomy 17 Cyclophosphamide 15 Radiation 13 Drug Therapy 13 folfirinox 12 Endoscopic Ultrasound-Guided Fine Needle Aspiration 12 irinotecan sucrosofate 11 Sorafenib 11 S 1 (combination) 11 Paclitaxel 11 Neoadjuvant Therapy 11 Ipilimumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05493995 2024-05-09

PAAG

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡